What a Grade 3 finding on the patella actually means

Reading 'Grade 3 chondral damage' on a patellar MRI report can feel alarming. The practical translation: more than half the cartilage thickness on the underside of your kneecap has been lost, but the underlying bone is still covered. That single distinction — bone plate intact — is what separates Grade 3 from end-stage Grade 4, where cartilage is gone and bare bone is exposed.

The ICRS/modified Outerbridge scale runs from Grade 0 (normal) to Grade 4. Grade 3 carries four sub-grades that reflect how far the damage has progressed through the remaining cartilage layers. In 3A and 3B, tissue loss stops above or at the calcified cartilage layer, leaving more structural scaffolding in place. In 3C and 3D, the damage extends through that calcified layer — 3D lesions also produce surface blistering over a large zone of deep underlying loss. The sub-grade matters clinically because it influences how much living cartilage matrix still remains to support any repair.

Cartilage has no direct blood supply, so it cannot mount a spontaneous healing response at this depth. A Grade 3 lesion will not quietly resolve on its own, but it does not necessarily race toward Grade 4 either — progression rates vary considerably between patients and depend heavily on loading patterns and joint mechanics. What the finding does signal is that specialist assessment is warranted: the window for biological repair is open, but it is not indefinite.

Plain X-ray will almost always look normal at this stage. MRI is the only reliable way to visualise focal patellar cartilage damage, characterise the sub-grade, and measure defect size — all of which shape the treatment options available.

Whether the joint is still in the preservation window

The short answer is yes — but conditionally. At Grade 3, the subchondral bone plate remains intact, and that single anatomical fact keeps cartilage-preserving interventions on the table. The preservation window closes at Grade 4, when the bone surface is exposed and the pathway shifts toward osteochondral reconstruction or, ultimately, joint replacement.

Two variables determine how much of that window is still usable. The first is sub-grade: a 3A or 3B lesion leaves the calcified cartilage layer available as a biological platform for repair procedures, whereas by 3C or 3D that foundation is considerably thinner — something a specialist will weigh when advising on technique. The second variable is defect size. Evidence broadly places a threshold around 2–4 cm²: smaller focal defects are eligible for the widest range of repair options, while defects at or above roughly 3 cm² tend to favour cell-based approaches over marrow-stimulation techniques, based on outcome data from the SUMMIT trial comparing MACI with microfracture at two and five years.

What the evidence does not yet offer is a patellar-specific natural-history study — precise figures for how quickly an untreated Grade 3 patellar lesion progresses are not well established. The conceptual case for acting within this window is strong, but individual prognosis depends on loading patterns, mechanical aetiology, and sub-grade findings that only a specialist assessment can properly weigh. Neither false urgency nor false reassurance is warranted here.

Why symptoms and scan findings rarely match exactly

Scan grade and symptom intensity frequently diverge — and that divergence matters for how an MRI report should be read. A patient with Grade 3 patellar damage may experience remarkably little pain if joint loading is well-distributed; equally, someone with relatively mild morphological change on imaging can suffer significant anterior knee pain when patellar maltracking, a high Q-angle, or weak hip abductors are concentrating force onto a small cartilage area. The mechanical environment shapes pain experience independently of what the grading system records.

This is why an MRI report is one input into a specialist assessment rather than a standalone verdict. The referring consultant weighs the scan against symptom history, physical examination findings, and the patient's functional trajectory — all of which can look very different between two patients whose scans appear identical on paper.

Some specialists also use advanced compositional sequences — T2 mapping, T1ρ imaging, or dGEMRIC — which can detect biochemical cartilage changes before visible morphological loss appears. These tools can help stratify urgency within Grade 3 when the clinical picture is ambiguous.

The practical upshot is that two people presenting with the same Grade 3 MRI report may reasonably be offered quite different management plans, depending on their mechanical profile, symptom pattern, and the degree to which day-to-day function has been affected.

Conservative care as the essential first layer

Mechanical correction comes first — not as a placeholder while awaiting something more definitive, but as an active intervention that directly shapes whether any subsequent treatment succeeds.

The central target is patellar tracking. When the patella rides outside its trochlear groove due to muscle imbalance or structural factors, cartilage loading becomes concentrated rather than distributed. Strengthening the vastus medialis oblique (VMO) alongside the hip abductors and external rotators reduces that concentration at source. This is why a targeted rehabilitation programme addressing quadriceps balance, hip control, and patellar alignment is considered the foundation of care for Grade 3 chondromalacia — not an optional preamble to the 'real' treatment.

Load management runs alongside the strengthening work. Temporarily modifying high-impact activities reduces symptom flare and protects the damaged zone while the mechanical programme takes effect.

Injection therapies — platelet-rich plasma and hyaluronic acid — may be introduced as adjuncts during this phase to manage pain or support the cartilage environment where rehabilitation alone provides insufficient relief. Their role is to support the programme, not substitute for it.

Critically, any surgical or regenerative procedure attempted without first correcting the underlying tracking deficit faces the same mechanical forces that produced the original damage. Failure to address aetiology risks recurrent cartilage loading regardless of what is used to repair it. Conservative care is also the phase that reveals which patients genuinely need escalation — and prepares the joint environment to make that escalation as effective as possible.

Repair options at Grade 3, matched to lesion size

Defect dimensions are the primary variable guiding which repair technique a specialist will recommend — and understanding the size thresholds helps explain why two patients with identical Grade 3 MRI reports may leave clinic with quite different options on the table.

Smaller defects (up to approximately 2–4 cm²)

For focal lesions at this scale, marrow-stimulation techniques such as microfracture remain a first-line surgical choice: small perforations are made in the subchondral plate to recruit blood-borne progenitor cells into the defect. Osteochondral autograft transfer (mosaicplasty) — transplanting cylindrical plugs of healthy cartilage and bone from a lower-load zone — is an established theatre-based alternative at this size range.

Larger defects (approximately 3 cm² and above)

Cell-based reconstruction is better supported by trial evidence at this threshold. The SUMMIT RCT found superior KOOS pain and function scores with MACI (matrix-induced autologous chondrocyte implantation) over microfracture at both two- and five-year follow-up — the data most directly informing the ≥3 cm² decision. STACi, a single-stage scaffold-based cell therapy, extends cell-based repair to geometrically complex defects where a two-stage procedure is impractical. Both are theatre-based procedures.

Injectable scaffold — a less invasive preservation option

ChondroFiller injection occupies a different point on the invasiveness spectrum: an acellular collagen scaffold delivered as an ultrasound-guided outpatient procedure, without theatre admission or general anaesthesia. Once placed, the matrix recruits the patient's own progenitor cells to support new cartilage formation — scaffold-supported, matrix-induced chondrogenesis rather than guaranteed regrowth. Recovery demands differ materially from the surgical options above.

One important caveat across all these techniques: the available outcome data — including the SUMMIT trial — derive predominantly from femoral condyle studies. Patellar-specific evidence remains limited, and individual suitability depends on a specialist assessment that weighs defect geometry, sub-grade, mechanical aetiology, and the patient's functional goals.

Getting assessed at the London Cartilage Clinic

Timing matters more at Grade 3 than at any earlier stage. With subchondral bone still intact but more than half the cartilage depth already compromised, the structural conditions that make preservation viable can close without obvious warning — a point that rarely appears in the standard GP letter accompanying an MRI report.

A specialist assessment at the London Cartilage Clinic combines imaging review, biomechanical examination, and a discussion of functional goals before any treatment decision is made. The aim is to establish what is driving the cartilage stress — tracking deficit, load pattern, muscle imbalance — and map that against defect geometry, sub-grade, and the patient's priorities. That mapping determines whether conservative optimisation, the ChondroFiller injection pathway, or a surgical referral is the appropriate next step; no single modality is assumed from the outset.

Professor Paul Y. F. Lee leads the ChondroFiller injection service in the UK; placement precision and application technique are understood to be material to outcomes with this type of scaffold.

Assessment is available at the London Cartilage Clinic on Harley Street. Book at londoncartilage.com.

1. [1] Chondromalacia patellae. https://en.wikipedia.org/?curid=1944613 https://en.wikipedia.org/?curid=1944613